Circulating microRNAs as diagnostic biomarkers for pancreatic cancer

2015 ◽  
Vol 15 (12) ◽  
pp. 1525-1529 ◽  
Author(s):  
Tessa Y.S. Le Large ◽  
Laura L. Meijer ◽  
Mireia Mato Prado ◽  
Geert Kazemier ◽  
Adam E. Frampton ◽  
...  
2019 ◽  
Vol Volume 12 ◽  
pp. 6665-6684 ◽  
Author(s):  
Jinru Xue ◽  
Erna Jia ◽  
Na Ren ◽  
Andrew Lindsay ◽  
Haixin Yu

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jiang Chen ◽  
Hongyu Li ◽  
Wenda Xu ◽  
Xiaozhong Guo

Abstract Background Pancreatic cancer (PC) is a devastating disease that has a poor prognosis and a total 5-year survival rate of around 5%. The poor prognosis of PC is due in part to a lack of suitable biomarkers that can allow early diagnosis. The lysophospholipase autotaxin (ATX) and its product lysophosphatidic acid (LPA) play an essential role in disease progression in PC patients and are associated with increased morbidity in several types of cancer. In this study, we evaluated both the potential role of serum LPA and ATX as diagnostic markers in PC and their prognostic value for PC either alone or in combination with CA19-9. Methods ATX, LPA and CA19-9 levels were evaluated using ELISA of serum obtained from PC patients (n = 114) healthy volunteers (HVs: n = 120) and patients with benign pancreatic diseases (BPDs: n = 94). Results Serum levels of ATX, LPA and CA19-9 in PC patients were substantially higher than that for BPD patients or HVs (p < 0.001). The sensitivity of LPA in early phase PC was 91.74% and the specificity of ATX was 80%. The levels of ATX, LPA and CA19-9 were all substantially higher for early stage PC patients compared to levels in serum from BPD patients and HVs. The diagnostic efficacy of CA19-9 for PC was significantly enhanced by the addition of ATX and LPA (p = 0.0012). Conclusion Measurement of LPA and ATX levels together with CA19-9 levels can be used for early detection of PC and diagnosis of PC in general.


2018 ◽  
Vol 56 (6) ◽  
pp. 869-879 ◽  
Author(s):  
Alena Kopkova ◽  
Jiri Sana ◽  
Pavel Fadrus ◽  
Ondrej Slaby

Abstract Cerebrospinal fluid (CSF) is a body fluid that has many important functions and is in direct contact with the extracellular environment of the central nervous system (CNS). CSF serves as both the communication channel allowing the distribution of various substances among the CNS cells and the storage facility for the waste products these cells release. For these reasons, CSF is a potential source of diagnostic biomarkers of many CNS diseases, including brain tumors. Recent studies have revealed that CSF also contains circulating microRNAs (miRNAs), short non-coding RNAs that have been described as biomarkers in many cancers. However, CSF miRNAs are difficult to detect, which is why researchers face major challenges, including technological difficulties in its detection and its lack of standardization. Therefore, this review aims (i) to highlight the potential of CSF miRNAs as diagnostic, prognostic and predictive biomarkers in brain tumors, and (ii) to summarize technological approaches for detection of CSF miRNAs.


2021 ◽  
Vol 67 (06/2021) ◽  
Author(s):  
Weigen Wu ◽  
Xiaoping Xia ◽  
Chen Cheng ◽  
Lili Niu ◽  
Jianguo Wu ◽  
...  

2020 ◽  
Vol 11 (6) ◽  
pp. 1325-1333 ◽  
Author(s):  
Jia Wei ◽  
Lu Yang ◽  
Yi-ning Wu ◽  
Jian Xu

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2767
Author(s):  
Jiawei Li ◽  
Xin Guan ◽  
Zhimin Fan ◽  
Lai-Ming Ching ◽  
Yan Li ◽  
...  

Breast cancer is the most common cancer in women worldwide. Accurate early diagnosis of breast cancer is critical in the management of the disease. Although mammogram screening has been widely used for breast cancer screening, high false-positive and false-negative rates and radiation from mammography have always been a concern. Over the last 20 years, the emergence of “omics” strategies has resulted in significant advances in the search for non-invasive biomarkers for breast cancer diagnosis at an early stage. Circulating carcinoma antigens, circulating tumor cells, circulating cell-free tumor nucleic acids (DNA or RNA), circulating microRNAs, and circulating extracellular vesicles in the peripheral blood, nipple aspirate fluid, sweat, urine, and tears, as well as volatile organic compounds in the breath, have emerged as potential non-invasive diagnostic biomarkers to supplement current clinical approaches to earlier detection of breast cancer. In this review, we summarize the current progress of research in these areas.


2018 ◽  
Vol 01 (09) ◽  
Author(s):  
Hongpei Wu ◽  
Bojun Bao ◽  
Hui Cong ◽  
Jinxia Liu ◽  
Feng Jiang ◽  
...  

2012 ◽  
Vol 107 (12) ◽  
pp. 1987-1996 ◽  
Author(s):  
C I Jones ◽  
M V Zabolotskaya ◽  
A J King ◽  
H J S Stewart ◽  
G A Horne ◽  
...  

2015 ◽  
Vol 6 (12) ◽  
pp. 1206-1213 ◽  
Author(s):  
Xiaoling Wu ◽  
Xiaohui Tan ◽  
Sidney W. Fu

2015 ◽  
Vol 60 (2) ◽  
pp. 247-254 ◽  
Author(s):  
Naomi L. Cook ◽  
Tamara N. Pereira ◽  
Peter J. Lewindon ◽  
Ross W. Shepherd ◽  
Grant A. Ramm

Sign in / Sign up

Export Citation Format

Share Document